This is a preview of subscription content, log in via an institution to check access.
Reference
Guirgis HM. Costs of the immune check point inhibitors versus survival ratio in first-line non-small lung cancer, cost bundling proposal. 57th Annual Meeting of the American Society of Clinical Oncology : abstr. e21034, 4 Jun 2021. Available from: URL: https://meetinglibrary.asco.org/record/200981/abstract
Rights and permissions
About this article
Cite this article
Bundling immune checkpoint inhibitor negotiations a less costly option for NSCLC. PharmacoEcon Outcomes News 883, 5 (2021). https://doi.org/10.1007/s40274-021-7876-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7876-8